Breaking News, Collaborations & Alliances

Merck, Samsung Bioepis To Develop Diabetes Biosimilar

Insulin glargine candidate to enter Phase III Trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck and Samsung Bioepis Co., Ltd., have expanded their biosimilars collaboration to develop, manufacture and commercialize MK-1293, an insulin glargine candidate currently in Phase III development for the treatment of type 1 and type 2 diabetes.   Merck and Samsung Bioepis will collaborate on clinical development, regulatory filings and manufacturing. If approved, Merck will be responsible for commercialization. The initial collaboration established in February 2013 was to develop and commerci...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters